What the Pentadecanoic Acid Artery Plaque Study Shows for Humans

October 14, 2026 · Science

What Happened in the Mice, and What Did Not Happen in People

The pentadecanoic acid artery plaque study showed that the fatty acid cut aortic plaque buildup by about half in male mice, but current evidence does not show that it clears arteries in humans. Researchers at Sun Yat-sen University and Shenzhen Bay Laboratory in China published the findings in Nature after testing the molecule in animals bred for atherosclerosis. The team reported their results in October 2026, as detailed by MedicalXpress.

The animal protocol tested two distinct administration schedules in male mice fed a high-fat diet. In the first experiment, administering living Bacteroides uniformis bacteria for 12 weeks lowered low-density lipoprotein (LDL) cholesterol and reduced aortic plaque accumulation. In the second experiment, giving pentadecanoic acid directly three times a week for eight weeks produced lower blood cholesterol and reduced plaque buildup by about half in the treated mice.

None of these plaque measurements took place in a human patient. The only published randomized human trial evaluated 88 women with non-alcoholic fatty liver disease (NAFLD), tracking changes in liver fat and blood cholesterol rather than arterial plaque. In addition, an analysis reported by Nature's news team and relayed by MedicalXpress found no link between circulating blood levels of the fatty acid and cardiovascular disease rates.

The Mechanism, and Why It Is the Convincing Part

Pentadecanoic acid lowers circulating cholesterol by inhibiting the exact enzyme responsible for cholesterol synthesis in the liver. Laboratory tests revealed that the molecule binds directly to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the primary catalytic target of pharmaceutical statins. When intracellular cholesterol manufacturing drops, liver cells respond by producing more surface low-density lipoprotein (LDL) receptors to pull circulating particles out of the blood.

This dual action means the liver produces less cholesterol while actively removing existing particles from circulation. The researchers confirmed that pentadecanoic acid, an odd-chain saturated fatty acid also known as C15:0, was the specific compound driving this cellular uptake. They isolated the substance directly from the fluid surrounding active bacterial cultures after screening candidates on laboratory-grown liver cells.

Three laboratory checks connected the bacterial product to the arterial benefit in mice. Heat-killed bacteria failed to provide protection, showing that living microbes were required to generate the beneficial effect. Disabling LDL-receptor production specifically in the mouse liver eliminated the vascular protection normally provided by both the bacterium and the fatty acid.

The investigators engineered bacterial strains that synthesized lower amounts of pentadecanoic acid. These altered bacteria still successfully colonized the mouse gut but offered substantially weaker protection against aortic plaque formation. Together, these experimental controls demonstrated that the odd-chain fatty acid was directly responsible for the vascular outcomes observed in the rodents.

Sharing a Target Is Not Sharing an Evidence Base

Inhibiting HMG-CoA reductase demonstrates biological plausibility, but sharing an enzyme target does not make an unproven molecule equivalent to a statin. Statins have human outcome trials behind them. In contrast, the vascular evidence for this odd-chain fatty acid statin target remains restricted to plaque measurements in male rodents.

Nobody should discontinue or adjust a prescribed statin medication based on this experimental research. Patients looking to optimize their lipid profiles should review our analysis of apolipoprotein B testing before discussing therapeutic adjustments with their physician.

What the One Human Trial Actually Measured

The only randomized controlled trial investigating pentadecanoic acid in humans focused on non-alcoholic fatty liver disease rather than arterial health. Published by Chooi and colleagues under digital object identifier 10.1016/j.ajcnut.2023.11.013 and registered as NCT05259475, the TANGO trial enrolled 88 Chinese females. This double-blinded, parallel-design study lasted 12 weeks and compared three separate interventions.

The protocol assigned 31 participants to an Asian-adapted Mediterranean diet with C15:0 supplementation, 28 to the diet without supplementation, and 29 to a habitual diet control group. Intention-to-treat analysis showed weight loss of 4.0 ± 0.5 kg (5.3%) in the supplemented diet arm, 3.4 ± 0.5 kg (4.5%) in the unsupplemented diet arm, and 1.5 ± 0.5 kg (2.1%) in the control arm. Liver proton density fat fraction fell by 33% in the supplemented diet group, 30% in the diet-only group, and 10% in the control group.

Both dietary intervention groups achieved statistically significant improvements compared to control across body weight, liver fat fraction, total cholesterol, gamma-glutamyl transferase (GGT), and triglycerides. The specific benefit attributable to pentadecanoic acid was narrow: it produced an incremental reduction in LDL cholesterol and increased the relative abundance of Bifidobacterium adolescentis. The authors concluded that C15:0 supplementation lowers LDL cholesterol and shifts the microbiome, but the background Mediterranean diet clearly drove the majority of clinical improvements.

The TANGO trial did not image arteries, measure vascular calcification, or evaluate atherosclerotic plaque. The trial publication also omitted the specific milligram dose administered to participants in its abstract, meaning human dosing cannot be determined from that report. These findings show metabolic activity in hepatic tissue, but they provide no confirmation of arterial plaque reduction in human patients.

The Null Result and the Declared Interests

Observational evidence from human population studies does not support the idea that higher pentadecanoic acid levels prevent cardiovascular disease. A 2026 analysis of two long-running human cohorts, reported by the news team at Nature and relayed through MedicalXpress, found no association between circulating blood levels of the molecule and lower cardiovascular disease rates. Cardiovascular specialist Ben Chen of Australia's Monash Victorian Heart Institute told Nature's news team that "the clinical evidence supporting a cardiovascular benefit remains limited".

Several limitations in the laboratory design restrict how broadly the findings can be applied. The researchers performed their plaque experiments exclusively on male mice, leaving potential sex differences in vascular response completely untested. The study authors explicitly noted that diverse human dietary patterns and complex native gut communities could substantially alter bacterial metabolism compared to laboratory animal models.

Commercial and intellectual property interests also surround the research. Study co-author Xiangyu Mou disclosed a pending patent covering the therapeutic use of pentadecanoic acid against atherosclerosis. Furthermore, the compound is already marketed as a heart-health supplement.

No Test Tells You Your Own Level

No commercial stool panel or at-home microbiome test measures your gut bacteria's actual production of pentadecanoic acid. None of these commercial tests measure what this research turns on. At Longevity Benchmark, we review these diagnostic tools regularly and explain their technical constraints in our guide on whether gut health tests are accurate.

A standard test might confirm the presence of Bacteroides uniformis, but knowing a species is present does not tell you if it produces active fatty acids. We documented the identical limitation in our guide on colon butyrate, where a stool test cannot tell you how much butyrate you make. Before purchasing consumer kits, readers can consult our review of the best gut health test options to understand what stool sequencing can and cannot deliver.

Food sources also fail to offer a simple shortcut for plaque prevention. While pentadecanoic acid occurs naturally in dairy fat, the molecule's presence in food is not evidence that eating dairy fat reduces plaque. Our broader gut health educational resources and our summary of the microbiome calorie absorption model explore how intestinal microbes interact with dietary inputs.

What Would Change This Read

Demonstrating that pentadecanoic acid reduces arterial plaque in humans would require prospective clinical trials using verified vascular imaging endpoints. Researchers would need larger human trials evaluating vascular endpoints across patient cohorts. The authors of the Nature paper stated that future human studies must establish whether direct supplementation or microbial stimulation can safely reduce atherosclerosis.

Preclinical validation also requires testing the intervention in female animal models to evaluate whether the anti-atherosclerotic mechanism functions identically across sexes. Until those rigorous human trials report data, the rodent plaque reductions remain an exploratory laboratory finding rather than an actionable clinical strategy. Readers evaluating the supplement question can read our review analyzing whether fatty15 works.

Our research framework evaluates emerging scientific literature against human clinical outcomes rather than preclinical rodent models, as detailed in our methodology. For any reader evaluating this science today, the sensible next step is to discuss verified lipid management strategies with a physician rather than assuming this pentadecanoic acid artery plaque study justifies self-treatment.

Sources

• Nature, doi.org. Source for the study by Yin C, et al., 'A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice,' published in 2026 with DOI 10.1038/s41586-026-11142-x, detailing the Bacteroides uniformis experiments, pentadecanoic acid isolation, HMG-CoA reductase inhibition, LDL receptor upregulation, and plaque reduction in male mice, accessed via reporting on 14 October 2026.
• MedicalXpress, medicalxpress.com. Source for news reporting on the Nature paper, the attribution to Sun Yat-sen University and Shenzhen Bay Laboratory, the 8-week and 12-week mouse study durations, the cohort analysis finding no cardiovascular association, the quote from Ben Chen, and co-author Xiangyu Mou's patent disclosure, accessed 14 October 2026.
• The American Journal of Clinical Nutrition, doi.org. Source for the TANGO randomized controlled trial by Chooi YC, et al., evaluating Asian-adapted Mediterranean diet and pentadecanoic acid in 88 Chinese females with non-alcoholic fatty liver disease over 12 weeks, accessed 14 October 2026.
• ClinicalTrials.gov, clinicaltrials.gov. Source for the clinical trial registration record of the TANGO study under identifier NCT05259475, accessed 14 October 2026.